Načítá se...

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

To determine when patients with incomplete responses on second-line tyrosine kinase inhibitor (2TKI) therapy should consider alternative treatment, we analyzed the outcome of 113 patients receiving nilotinib (n = 43) or dasatinib (n = 70) after imatinib failure. After 12 months of 2TKI therapy, pati...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tam, Constantine S., Kantarjian, Hagop, Garcia-Manero, Guillermo, Borthakur, Gautam, O'Brien, Susan, Ravandi, Farhad, Shan, Jenny, Cortes, Jorge
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2008
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4082324/
https://ncbi.nlm.nih.gov/pubmed/18492956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-141580
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!